{"id":"igi-10","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IGI appears to be an investigational immunoglobulin product in development by Takeda. The 10% formulation likely refers to a concentration or dosing specification. As a Phase 3 asset with limited public disclosure, the precise molecular mechanism and target remain proprietary, though immunoglobulin therapeutics typically work through Fc receptor binding to modulate immune cell activation and antibody-dependent cellular responses.","oneSentence":"IGI is an immunoglobulin-based therapeutic that modulates immune function through Fc receptor engagement.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:34.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT05084053","phase":"PHASE3","title":"A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-01-19","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)","enrollment":26},{"nctId":"NCT05513586","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-09-13","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":15},{"nctId":"NCT05150340","phase":"PHASE3","title":"A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-01-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":16},{"nctId":"NCT02955355","phase":"PHASE3","title":"Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-14","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":85},{"nctId":"NCT04578535","phase":"PHASE1","title":"A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2020-10-27","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT03277313","phase":"PHASE3","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-09-25","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT03116347","phase":"PHASE4","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-05-30","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":42},{"nctId":"NCT01485796","phase":"PHASE2, PHASE3","title":"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-29","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":54},{"nctId":"NCT01947595","phase":"NA","title":"Individualized Lifestyle Intervention in Subjects With Prediabetes","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2012-03","conditions":"Diabetes Mellitus Type 2","enrollment":1145}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-339","Gammagard Liquid","KIOVIG"],"phase":"phase_3","status":"active","brandName":"IGI, 10%","genericName":"IGI, 10%","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}